On August 29, 2019 Kyowa Kirin Co., Ltd., (Kyowa Kirin, President and CEO: Masashi Miyamoto) reported that Hisamitsu Pharmaceutical Co., Inc. (Hisamitsu Pharmaceutical, President and CEO: Kazuhide Nakatomi) has submitted a new drug application for the additional indications of opioid analgesic naïve cancer pain relief for the transdermal, pain management patch FENTOSTAPE (Development code: HFT-290, generic name: fentanyl citrate, "the product") in Japan (Press release, Kyowa Hakko Kirin, AUG 29, 2019, View Source [SID1234539111]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Hisamitsu Pharmaceutical has conducted the clinical study in opioid analgesic naïve cancer pain patients with the product (starting dose at 0.5mg) and confirmed the efficacy and safety of the product.

The product was granted the approval for the treatment of pain relief in various cancers that accompany moderate to severe pain in April 2010 and the additional indication approval for chronic pain in June 2014. In addition, the product was granted the additional approval of a new dose of 0.5mg in July 2018.

Kyowa Kirin and Hisamitsu Pharmaceutical have jointly carried out product distribution and activities of the provision and collection of information (1 brand, 2 channels) since June 2010. Through providing appropriate information of the product　with Hisamitsu Pharmaceutical, Kyowa Kirin looks forward to giving further contribution to improve quality of life in patients suffering from cancer pain or chronic pain.

Hisamitsu Pharmaceutical expects to receive a manufacturing and marketing approval of the additional indications by February 2021.

The Kyowa Kirin Group companies strive to contribute to the health and well-being of people around the world by creating new value through the pursuit of advances in life sciences and technologies.

On August 29, 2019 Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, reported that Jay Hagan, President and Chief Executive Officer of Regulus, will present a company overview at the Wells Fargo Healthcare Conference in Boston on Thursday, September 5, 2019 (Press release, Regulus, AUG 29, 2019, View Source [SID1234539128]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On August 29, 2019 MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), reported that MediciNova will attend the Morgan Stanley Global Healthcare Conference which will be held at the Grand Hyatt New York in New York City from September 9 – 11, 2019 (Press release, MediciNova, AUG 29, 2019, View Source [SID1234539146]). Yuichi Iwaki, MD, PhD, President and Chief Executive Officer, will be available for one-on-one meetings at this conference and investors may request a one-on-one meeting through Morgan Stanley.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On august 29, 2019 Nordic Nanovector ASA (OSE: NANO) reported that it will host a R&D Day in Oslo on Tuesday, 17 September 2019 from 9:30am to 12:30pm CEST (Press release, Nordic Nanovector, AUG 29, 2019, View Source [SID1234553446]). The programme will include presentations from three external experts and by Nordic Nanovector’s senior management team. An update on the median Duration of Response (mDoR) of Betalutin treatment in the LYMRIT 37-01 trial will also be given during the day.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Venue: Thon Hotel Vika Atrium, Munkedamsveien 45, 0250 Oslo

Meeting Room: Auditorium

To register to attend, please e-mail [email protected] by 13 September 2019.

The R&D Day will be recorded as a webcast and will be available at www.nordicnanovector.com in the section: Investors & Media.

The presentations will be available at www.nordicnanovector.com in the section: Investors & Media/Reports and Presentation/2019.

The preliminary programme is as follows;

09.30-09.50 Nordic Nanovector’s pipeline – Strategic insights Eduardo Bravo, CEO

09.50-10.10 Radioimmunotherapy – Preclinical results with Betalutin and comparison of alpha and beta emitters Dr Jean-Pierre Pouget*

10.10-10.40 Future vision for R&D at Nordic Nanovector Dr Jostein Dahle, CSO

10:40-10:50 Introduction to clinical sessions Dr Lisa Rojkjaer, CMO

10.50-11.20 Unmet medical needs and therapeutic landscape for recurrent follicular and marginal zone lymphoma Prof. Pier Luigi Zinzani*

11:20-11:30 Coffee Break

11.30-12:00 Novel biologic combinations with Betalutin Dr Arne Kolstad*

12.00-12.20 BLA readiness: CMC commercial plans Dr Marco Renoldi, COO

12.20-12.30 Q&A

*The external experts’ speakers are:

Dr J.P. Pouget, PhD, Radiobiology and targeted radiotherapy group Montpellier Cancer Research Institute (IRCM), French National Institute of Health and Medical Research (INSERM).
Prof. P. L. Zinzani, Professor of Hematology, Institute of Hematology "L. e A. Seràgnoli", University of Bologna.
Dr A. Kolstad MD, PhD, senior consultant in Medical Oncology and Radiation Therapy, Dept of Oncology Oslo University Hospital, The Norwegian Radium Hospital.

On August 29, 2019 LabCorp (NYSE: LH) reported it will participate at the Morgan Stanley Global Healthcare Conference (Press release, LabCorp, AUG 29, 2019, View Source [SID1234539112]). LabCorp’s presentation is planned for Monday, Sept. 9, 2019 at 9:55 a.m. ET.
A live audio webcast will be available via the Company website at www.LabCorp.com and archived for replay.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!